Celsion (NASDAQ:CLSN) Shares Cross Above 200-Day Moving Average of $0.00

Celsion Co. (NASDAQ:CLSN) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $1.77. Celsion shares last traded at $1.77, with a volume of 149 shares trading hands.

Several research firms have recently issued reports on CLSN. ValuEngine lowered shares of Celsion from a “hold” rating to a “sell” rating in a research report on Thursday, June 6th. Zacks Investment Research raised shares of Celsion from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Finally, Brookline Capital Management restated a “buy” rating on shares of Celsion in a report on Thursday, July 25th.

The firm has a market cap of $36.25 million, a P/E ratio of -2.51 and a beta of 1.92. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.22 and a current ratio of 4.22. The stock’s fifty day moving average price is $1.78.

Celsion (NASDAQ:CLSN) last announced its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Celsion had a negative net margin of 1,954.60% and a negative return on equity of 65.35%. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, analysts anticipate that Celsion Co. will post -1.13 EPS for the current fiscal year.

A hedge fund recently raised its stake in Celsion stock. BlackRock Inc. increased its stake in Celsion Co. (NASDAQ:CLSN) by 21.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 142,426 shares of the biotechnology company’s stock after buying an additional 25,548 shares during the period. BlackRock Inc. owned 0.76% of Celsion worth $202,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 4.76% of the company’s stock.

About Celsion (NASDAQ:CLSN)

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

Featured Story: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.